# A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

> **NCT03215030** · PHASE1,PHASE2 · TERMINATED · sponsor: **Teva Branded Pharmaceutical Products R&D LLC** · enrollment: 272 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Modakafusp alfa
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03215030
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-04
- **Primary completion:** 2024-07-01
- **Final completion:** 2024-11-07
- **Target enrollment:** 272 (ACTUAL)
- **Why stopped:** Terminated by the sponsor for strategic reasons
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03215030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03215030, "A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03215030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*